Skip to content
Menu

Piper Sandler Maintains Overweight on Bristol-Myers Squibb, Lowers Price Target to $78

Benzinga Newsdesk 3 weeks ago

Analyst RatingsNewsPrice TargetHot

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

Piper Sandler analyst David Amsellem maintains Bristol-Myers Squibb (NYSE:BMY) with a Overweight and lowers the price target from $82 to $78.

Piper Sandler analyst David Amsellem maintains Bristol-Myers Squibb (NYSE:BMY) with a Overweight and lowers the price target from $82 to $78.

Read at benzinga.com

← All stock news